Is Aldeyra Therapeutics waving red flags with consequences?

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug growth, enterprise, Wall Road, and biotechnology. He’s additionally a co-host of the weekly biotech podcast The Readout Loud and creator of the publication Adam’s Biotech Scorecard. You possibly can attain Adam on Sign at stataf.54.

That is the web model of Adam’s Biotech Scorecard, a subscriber-only publication. STAT+ subscribers can enroll right here to get it delivered to their inbox.

Welcome again! Aldeyra Therapeutics is complaining about quick sellers within the run-up to an FDA approval determination. The Vertex period of frictionless commerce is coming to an finish. And with Doug Ingram’s departure and its future murky, Sarepta is at a CEO crossroads. 

Purple eyes, pink flags. Aldeyra calls out quick sellers

Purple flags — I’m referring to the company actions that ship a “be cautious” sign to buyers — are available all styles and sizes. Some are blaring warning indicators, others are extra refined.